Results 111 to 120 of about 16,909 (214)

Real‐world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron‐overloaded patients

open access: yes
British Journal of Haematology, Volume 208, Issue 6, Page 2320-2325, June 2026.
Barbara Gianesin   +29 more
wiley   +1 more source

Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing.

open access: yes, 2017
A hallmark of diabetes mellitus is the breakdown of almost every reparative process in the human body, leading to critical impairments of wound healing. Stabilization and activity of the transcription factor hypoxia-inducible factor (HIF)-1?
Duscher, Dominik;Januszyk, Michael;Maan, Zeshaan N;Whittam, Alexander J;Hu, Michael S;Walmsley, Graham G;Dong, Yixiao;Khong, Sacha M;Longaker, Michael T;Gurtner, Geoffrey C
core   +1 more source

Failure of deferoxamine, an iron chelator, to improve neurologic outcome following complete cerebral ischemia in dogs.

open access: yes, 1987
Eleven minutes of complete cerebral ischemia was produced in 17 dogs by temporary ligation of the venae cavae and aorta. Immediately prior to the ischemic episode, 7 dogs received deferoxamine, an iron chelator, 50 mg/kg i.v., and 10 dogs received an ...
W L Lanier   +3 more
core   +1 more source

Effect of Deferoxamine on Late Deaths Following CPR in Rats

open access: yes, 1986
The iron chelating agent deferoxamine was studied in an animal model as post-resuscitation therapy to prevent late deaths and brain damage following total circulatory arrest and resuscitation. Cardio-respiratory arrest was induced by injection of cold, 1%
Babbs, Charles F   +2 more
core  

Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice

open access: yesJournal of Neuroinflammation
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available.
Yulin Liu   +5 more
doaj   +1 more source

Effect of intravenous Deferoxamine concomitant use with blood transfusion on serum ferritin in thalassemia major patients [PDF]

open access: yes
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to iron overload with its complications. So, other methods with better toleration and reduction of Deferoxamine consumption are necessary. The present study
عرقچین, سمیرا   +3 more
core  

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

The impact of intravenous deferoxamine during the blood transfusion on reduction of serum ferritin in thalassemia patients [PDF]

open access: yes
Introduction: A blood transfusion in patients with thalassemia major is a important treatment base. Iron overload resulted from Long-term transfusion-related using iron chelators particularly by the deferoxamine can be reduced.
عرقچین, سمیرا   +2 more
core  

Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis

open access: yesCaspian Journal of Internal Medicine, 2017
Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine.
Gholamreza Badfar   +9 more
doaj  

Home - About - Disclaimer - Privacy